AI-identified biomarker-based test reduces need for prostate biopsies in men with high PSA levels
Published October 25, 2024
Written by Niven R. Narain, Ph.D., President & CEO, BPGbio for Today’s Clinical Lab
Prostate cancer remains a significant health challenge, with prostate-specific antigen (PSA) testing failing to accurately distinguish between malignant prostate cancers and benign conditions with similar symptoms, such as benign prostatic hyperplasia (BPH), resulting in 70 percent of prostate biopsies being negative. Recent scientific advancements highlight the potential of using artificial intelligence (AI) to identify novel biomarkers for diagnostic test development (as well as therapeutics design). The development of such biomarkers into diagnostic tests could enhance diagnostic precision and reduce unnecessary medical procedures.
Prostate cancer rates are rising
…
For the full story, please visit: Today’s Clinical Lab – Prostate Clarity
